Key takeaways
Rinvoq (upadacitinib) and Cimzia (certolizumab) are both medications used to treat inflammatory conditions like rheumatoid arthritis and Crohn's disease. However, they belong to different medication classes. Rinvoq is a Janus kinase (JAK) inhibitor, while Cimzia is a tumor necrosis factor (TNF) blocker. Rinvoq is taken orally, either as an extended-release tablet or an oral solution, and is typically taken once daily. In contrast, Cimzia is administered as an injection every 2 to 4 weeks. Rinvoq is available in both tablet and liquid forms, but Cimzia is only available as an injection. Common side effects of Rinvoq include upper respiratory infections and acne, while Cimzia may cause upper respiratory infections and skin rash. Both medications can increase the risk of infections, but Rinvoq also has a risk of causing blood clots and stomach tears. Additionally, Rinvoq is not recommended during pregnancy, whereas Cimzia might be okay, depending on a risk-benefit discussion with your prescriber. It's important to discuss with your healthcare professional which medication is best for your condition and lifestyle.
